BEAS-2B

Stimulus

Lipopolysaccharide

Experimental context

BEAS-2B + LPS

Stimulus parameters

dose: NOT_REPORTED; exposure duration: NOT_REPORTED

Evidence summary: Directly supports BEAS-2B use for airway epithelial inflammatory responses to LPS. BEAS-2B bronchial epithelial cells were assessed for LPS/sCD14/LBP-induced IL-6 and IL-8 release and compared with A-549 cells.

Interpretation: Used to study LPS-associated airway epithelial inflammatory responses in BEAS-2B.

Limitation: BEAS-2B is immortalized and is not equivalent to primary normal airway; responses differ from A549 and depend on experimental context.

Stimulus

House dust mite extract

Experimental context

BEAS-2B + HDM

Stimulus parameters

concentration: 300 ng/mL (figure experiment); exposure duration: NOT_REPORTED

Evidence summary: Directly supports BEAS-2B HDM application for airway inflammation, epithelial injury and barrier dysfunction studies. BEAS-2B airway epithelial cells were treated with HDM to mimic allergic asthma in vitro; experiments included NLRP3 activity, IL-1β/IL-18 release, pyroptosis and barrier integrity (300 ng/mL HDM in figure experiments). Adds independent support for HDM-induced airway epithelial injury applications using BEAS-2B. BEAS-2B bronchial epithelial cells were exposed to HDM and assessed for oxidative stress and DNA damage endpoints in an asthma-related experimental context.

Interpretation: Used to study HDM-associated airway inflammation, barrier dysfunction and injury responses in BEAS-2B.

Limitation: Mechanistic perturbation and a single immortalized line do not establish clinical asthma validity or rank the model against alternatives. The in-vitro arm addresses selected damage endpoints and does not reproduce the multicellular asthma airway or prove disease fidelity.